ELN and achalasia-alacrima syndrome: Batimastat, a synthetic peptide also known as BB-94, is a hydroxamic acid-based broad-spectrum inhibitor of MMPs, and it was demonstrated that systemic administration of BB-94 reduced aortic dilatation and medial elastin fragmentation in elastase-induced AAAs in rats, and also suppressed inflammatory cell infiltration (177).